Protocol Ledger

NCT04460807 · Phase III · TERMINATED

Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Interventional Phase III clinical trial protocol NCT04460807 sponsored by Ente Ospedaliero Ospedali Galliera in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-02-13 Enrollment: 23 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04460807
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)23 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04460807
Protocol FieldVerified Registry Value
NCT IdentifierNCT04460807
Consolidated Lead SponsorEnte Ospedaliero Ospedali Galliera
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment23 participants (ACTUAL)
Registered Start Date2020-02-13
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04460807
Hospital Research SiteLocationSite Profile
Azienda Ospedaliero Universitaria PisanaPisa, ItalyOpen Hospital Dossier ->
Fondazione IRCCS Policlinico San MatteoPavia, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI